CSSH-1
CSSH-3
CSSH-2

product

more>>

about us

dfgdf

what we do

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. was founded in 2000. On 19 August 2011, the company was listed on the Growth Enterprise Market of Shenzhen Stock Exchange (stock code 300255). The company has four production bases, nine subsidiaries, two overseas companies, and two joint ventures. The company is a biochemical pharmaceutical enterprise, integrating research and development, production, sales, and import and export trade. It is a key high-tech enterprise with products from heparin crude products to low molecular weight heparin injections and a complete heparin industrial chain in the field of heparin, and a leading pharmaceutical company in the production of domestic heparin products.

more>>
Quality policy

Quality of survival, management for efficiency, integrity and reputation, innovation and development.

more>>
  • Always puts the quality at the first place and strictly supervise the product quality of every process.

    Quality

    Always puts the quality at the first place and strictly supervise the product quality of every process.

  • Our Factory has grown into a Premier  Certified manufacturer of High quality, Cost-Effective products

    Certificate

    Our Factory has grown into a Premier Certified manufacturer of High quality, Cost-Effective products

  • The company is a biochemical pharmaceutical enterprise, integrating research and development, production, sales, and import and export trade

    Manufacturer

    The company is a biochemical pharmaceutical enterprise, integrating research and development, production, sales, and import and export trade

Exhibition Style

  • Team 796

    Team

  • Founded Time September 28, 2000

    Founded Time

  • Number of patents 11

    Number of patents

  • Total exports in 2019 68 million dollars

    Total exports in 2019

news

Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. was founded in 2000.

Innovation leads development CSBIO: Net profit increased by 20.13% in the first half of the year

On August 27, the performance of Changshan Pharmaceutical’s 2021 mid-year report showed that in the first half of this year, the company achieved operating income of 1.417 billion yuan, an increase of 40.36% over the same period of the previous year; net profit attributable to shareholders ...
more>>

Chinese Physician’s Day

To build a dream together in the centennial birthday The doctor is responsible for practicing the original intention August 19, 2021 It’s the fourth Chinese doctor’s day Changshan Pharmaceutical provides all “Respect for life, save the dying and heal the wounded Willing to give ...
more>>

Recognize thrombus

Arteriovenous Thromboembolism Divided into Venous thromboembolism and Arterial Thromboembolism Venous thromboembolism includ Pulmonary embolism and Deep vein thrombosis. Arterial Thromboembolism includ Stroke and heart attack. Venous thromboembolism Contains the following two situations : Pulmona...
more>>

Introduction to the new drug-ibenatide

Hebei Changshan Pharmaceutical Co., Ltd. and ConjuChem LLC of the United States signed a joint venture agreement. The two parties jointly established a Sino-foreign joint venture —Changshan Kaijiejian Biopharmaceutical Research and Development (Hebei) Co., Ltd.    With the increasing enr...
more>>

2021 US NCCN guidelines recommend: low molecular weight heparin is the first choice for VTE prevention in hospitalized tumor patients

Malignant tumors are the most important risk factor for venous thrombosis (VTE), and VTE has become the second leading cause of death for tumor patients. Studies have shown that the risk of VTE in cancer patients is at least 4 to 6 times higher than that in non-tumor patients, and VTE increases t...
more>>